Connecticut, Missouri, and New Hampshire join 10 other states considering psychedelics bills.
Connecticut, Missouri, and New Hampshire join 10 other states considering psychedelics bills.
States so far include Alaska, Arizona, California, Hawaii, Indiana, Illinois, Massachusetts, Maryland, New Jersey, and Wisconsin.
The ketamine molecule is not FDA-approved in any formulation for the treatment of psychiatric disorders.
Clinical research indicates the potential for strong mental health applications.
These guidelines advise researchers on study design and other considerations as they develop medications that contain psychedelics.
